Archynetys Live news trend intelligence
▲ Peaking Business

Tempus AI Scoops Up Personalis For $1.5 Billion; But Shares Dive

Tempus AI is acquiring cancer-monitoring firm Personalis for $1.5 billion, though the announcement triggered a decline in share prices for both companies.

6sources
6articles
4velocity
+31%since first seen
10h agofirst detected

Velocity

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

The brief

Tempus AI has entered into a $1.5 billion stock deal to acquire Personalis, a firm specializing in cancer genomics and monitoring. The acquisition aims to integrate molecular residual disease (MRD) more tightly into the AI-enabled precision oncology platform operated by Tempus.

Coverage from Reuters, Quartz, and Fierce Biotech identifies Personalis as a cancer test maker and genomics partner. Financial reporting from Barron's and Investor's Business Daily emphasizes that shares for both companies sank following the news of the deal.

Future developments involve the integration of Personalis's capabilities into the Tempus precision oncology platform. Coverage does not specify the exact timeline for the deal's closing.

Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated just now.

Quick answers

What is the value of the acquisition?

The deal is valued at $1.5 billion.

How is the acquisition being funded?

According to Quartz, it is a stock deal.

How did the market react to the news?

Barron's and Investor's Business Daily report that shares for both Tempus AI and Personalis dived or sank.

Coverage (6)

Topics

Related trends